SCHEMBL442774

SCHEMBL442774

CCC(C)COC(=O)c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.78
ALDH1A1 P00352 2/20 0.62
ADRB2 P07550 2/20 0.58
ADRB1 P08588 2/20 0.58
ADRB3 P13945 2/20 0.58
LMNA P02545 1/20 0.58
TDP1 Q9NUW8 2/20 0.52
TSHR P16473 3/20 0.50
KMT2A Q03164 2/20 0.50
MAPK1 P28482 1/20 0.50
HIF1A Q16665 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
SLC1A5 Q15758 1/20 0.47
NPC1 O15118 3/20 0.47
MEN1 O00255 1/20 0.47
FFAR1 O14842 1/20 0.47
PRKCA P17252 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL571219 0.91 ALDH1A1 (0.69) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL5368475 0.91 MAPT (0.86) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL5959979 0.90 MAPT (0.74) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL9345545 0.88 MAPT (1.00) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL9345539 0.88 MAPT (1.00) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL5382671 0.88 MAPT (0.66) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL29096681 0.86 MAPT (0.97) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL14770230 0.86 MAPT (0.59) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL7296875 0.86 ALDH1A1 (0.62) MAPTALDH1A1ADRB2ADRB1ADRB3
Ethylene Glycol SCHEMBL11169176 0.86 ALDH1A1 (0.68) MAPTALDH1A1ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228525-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects ARBOR PHARMACEUTICALS, LLC 2021-07-29 US claimed
EP-2887934-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XenoPort, Inc. (US) 2015-07-01 EP claimed
US-20140350018-A9 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects XENOPORT, INC. (US) 2014-11-27 US claimed
US-8778991-B2 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use XENOPORT, INC. (US) 2014-07-15 US claimed
WO-2014031901-A1 METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF XENOPORT, INC. (US) 2014-02-27 WO claimed
US-20140057918-A1 Methods of Use for Monomethyl Fumarate and Prodrugs Thereof XENOPORT, INC. (US) 2014-02-27 US claimed
WO-2014031844-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XENOPORT, INC. (US) 2014-02-27 WO claimed
US-20140057917-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects XENOPORT, INC. (US) 2014-02-27 US claimed
EP-2650279-A2 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use XenoPort, Inc. (US) 2013-10-16 EP claimed
US-20120157523-A1 PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2012-06-21 US claimed
WO-2010022177-A2 PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2010-02-25 WO claimed
US-20100048651-A1 PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2010-02-25 US claimed
US-20260096991-A1 BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION XAMPLA LTD (GB) 2026-04-09 US disclosed
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
EP-4489592-B1 BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION XAMPLA LTD (GB) 2025-12-24 EP disclosed
US-20090220442-A1 SUNSCREEN COMPOSITION COMPRISING A DIBENZOYLMETHANE, AN AMINOHYDROXYBENZOPHENONE, A TRIAZINE AND A TRIAZOLE AS UV FILTERS JOHNSON & JOHNSON CONSUMER FRANCE, S.A.S. (FR) 2009-09-03 US disclosed
WO-2009027957-A2 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2009-03-05 WO disclosed
US-20080294083-A1 Orthopedic device OSSUR HF (IS) 2008-11-27 US disclosed
US-4219570-A Insect repellents and a method of repelling insects AJINOMOTO COMPANY, INCORPORATED (JP) 1980-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260096991-A1 BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION PCTP, CLK4, MTCL3 MAPT 146/4885ALDH1A1 4813/4885ADRB2 4073/4885
US-20120157523-A1 PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE FH, MGMT, BHMT2 MAPT 1222/4885ALDH1A1 2050/4885ADRB2 4142/4885
US-20140057917-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects FH, FAH, ALDOA MAPT 3738/4885ALDH1A1 626/4885ADRB2 4617/4885
US-20140057918-A1 Methods of Use for Monomethyl Fumarate and Prodrugs Thereof FH, FAH, DHFR MAPT 3834/4885ALDH1A1 1063/4885ADRB2 4763/4885
US-20140350018-A9 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects FH, FAH, ALDOA MAPT 3738/4885ALDH1A1 626/4885ADRB2 4617/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 MAPT 719/4885ALDH1A1 1420/4885ADRB2 250/4885
US-20100048651-A1 PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE FH, MGMT, BHMT2 MAPT 1222/4885ALDH1A1 2050/4885ADRB2 4142/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 MAPT 37/4885ALDH1A1 4768/4885ADRB2 1172/4885
US-20090220442-A1 SUNSCREEN COMPOSITION COMPRISING A DIBENZOYLMETHANE, AN AMINOHYDROXYBENZOPHENONE, A TRIAZINE AND A TRIAZOLE AS UV FILTERS CDC73, CUTA, TYR MAPT 1288/4885ALDH1A1 401/4885ADRB2 2573/4885
US-20210228525-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects FH, FAH, ALDOA MAPT 3738/4885ALDH1A1 626/4885ADRB2 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.